Cargando…

Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?

Detalles Bibliográficos
Autores principales:	Justo da Silva, Gustavo Jose, Bowen, T. Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093536/ https://www.ncbi.nlm.nih.gov/pubmed/33997526 http://dx.doi.org/10.1016/j.jacbts.2021.02.011

Ejemplares similares

Reply: Tolerating Large Preclinical Models of HFpEF But Without the Intolerance?
por: Sharp, Thomas E., et al.
Publicado: (2021)

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Reply: Diet-Induced Obesity HFpEF Murine Models
por: Valero-Muñoz, Maria, et al.
Publicado: (2018)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

The “Obesity Paradox” in Patients With HFpEF With or Without Comorbid Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2022)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping
por: Houstis, Nicholas E.
Publicado: (2020)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

Influence of antidiabetic medications on predictive aptitude of TyG index for HFpEF
por: Shimoda, Tomonari, et al.
Publicado: (2023)

OR19-2 Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) with Low and High Dose of Triiodothyronine: an Animal Model of Metabolic Syndrome with HFpEF
por: Almeida-Coelho, João, et al.
Publicado: (2022)

Prognostic Impact of Echocardiographic Congestion Grade in HFpEF With and Without Atrial Fibrillation
por: Abe, Haruhiko, et al.
Publicado: (2022)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities
por: Cuijpers, Ilona, et al.
Publicado: (2020)

Cat-apulting Toward a Molecular Understanding of HFpEF
por: Robinson, Emma L., et al.
Publicado: (2021)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
por: Arvidsson, Per M., et al.
Publicado: (2022)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
por: Zhu, Zhaowei, et al.
Publicado: (2021)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
por: Barilli, Maria, et al.
Publicado: (2022)

New antidiabetic therapy and HFpEF: light at the end of tunnel?
por: Tadic, Marijana, et al.
Publicado: (2021)

Electrophysiological findings in HFpEF patients presenting for AF ablation
por: Lee, J, et al.
Publicado: (2023)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

Worsening Renal Function and Adverse Outcomes in Patients with HFpEF with or without Atrial Fibrillation
por: Guo, Linjuan, et al.
Publicado: (2023)

Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents
por: Jasińska-Stroschein, Magdalena
Publicado: (2023)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3a9ouf6e7ltp4usoo68o529bep